ArticleEpilepsia2011
Remission and relapse in a drug-resistant epilepsy population followed prospectively.
Article in Epilepsia, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03475225 (Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of the Treatment of Vitamin D Deficiency in Drug-resistant Epilepsy
Who cites it
54 citing papers in PubMed.
- A Study on Protocol-based Treatment Change in Drug-resistant Epilepsy Patients in a Tertiary Care Center in Eastern India.Annals of Indian Academy of Neurology · 2026Article
- The scale for estimating prognosis of epilepsy to predict in patients with epilepsy: a 506-patient cohort study.BMC neurology · 2026Article
- Epilepsy and Placebo: A Literature Review.Neurologic clinics · 2026Review
- Use of cannabidiol for off-label treatment of patients with refractory focal, genetic generalised and other epilepsies.Neurological research and practice · 2025Article
- Neuropsychiatric tests and cognitive functions before and after epilepsy surgery in patients with drug-resistant epilepsy.Current journal of neurology · 2024Article
- Article
- A comprehensive prediction model of drug-refractory epilepsy based on combined clinical-EEG microstate features.Therapeutic advances in neurological disorders · 2024Article
- Identifying the mechanism of action of the Kv7 channel opener, retigabine in the treatment of epilepsy.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023Review
- Revisiting the concept of drug-resistant epilepsy: A TASK1 report of the ILAE/AES Joint Translational Task Force.Epilepsia · 2023Article
- Long-term epilepsy outcome dynamics revealed by natural language processing of clinic notes.Epilepsia · 2023Article
- Beyond seizure freedom: Dissecting long-term seizure control after surgical resection for drug-resistant epilepsy.Epilepsia · 2023Article
- Article
- Factors not considered in the study of drug-resistant epilepsy: Psychiatric comorbidities, age, and gender.Epilepsia open · 2022Review
- Multi-omic strategies applied to the study of pharmacoresistance in mesial temporal lobe epilepsy.Epilepsia open · 2022Review
- Abnormal electroencephalogram (EEG) after drug withdrawal is a risk factor for epilepsy recurrence in children: a systematic review and meta-analysis.Translational pediatrics · 2022Article
- Different Prognostic Patterns in Epilepsies and Considerations About the Denotations of Atypical Patterns.Noro psikiyatri arsivi · 2022Review
- Response to Sodium Channel blocking Antiseizure medications and coding polymorphisms of Sodium Channel genes in Taiwanese epilepsy patients.BMC neurology · 2021Article
- The Pharmacoresistant Epilepsy: An Overview on Existent and New Emerging Therapies.Frontiers in neurology · 2021Review
- Definitions and Risk Factors for Drug-Resistant Epilepsy in an Adult Cohort.Frontiers in neurology · 2021Article
- Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies.Neuropsychiatric disease and treatment · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeWe investigated the cumulative probability of seizure remission and relapse in an adult population with drug-resistant epilepsy and frequent seizures. In addition, we determined clinical predictors of remission and relapse in this population.
methodsIN 2003, we identified 246 patients at a single center with drug-resistant epilepsy defined as at least one seizure per month and failure of at least two antiepileptic drugs. These patients were followed prospectively (cohort design). We examined the cumulative probability of seizure remission and relapse in this population using Kaplan-Meier methodology. Clinical predictors of remission and relapse were also evaluated using Cox regression analysis. KEY
findingsThe estimated cumulative probability of 12-month seizure remission was 34.6% at 7 years in the entire population and 33.4% when limited to those without surgery. The risk for relapse after a 12-month period of seizure remission was 71.2% at 5 years. Negative predictors of seizure remission included developmental delay, symptomatic generalized epilepsy syndrome, duration of intractability, and number of antiepileptic drugs failed. Localization-related epilepsy was the only negative predictor of relapse. SIGNIFICANCE: Among patients with drug-resistant epilepsy, 5% per year enter seizure remission even with a follow-up of 6 years. However, a substantial proportion of these patients relapse after the first year following a remission. The large proportion of patients entering a significant remission gives these patients hope; however, caution should be advised when discussing the likelihood of future seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.